Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a potent inhibitor of DNA methylation, used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Decitabine is a potent inhibitor of DNA methylation, used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MmnhSpVv[3Srb36gRZN{[Xl? MoDINE42yqEQvF2= NX3GeZI2OjRiaB?= NFnjbnR4[XSnch?= MUXtc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=> Mli0NlUyOjNyOEK=
Eca109 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvOdVVKOC53L{KuOU82KM7:TR?= NVzBcVg5OjRxNEivO|IhcA>? NFPMRWh4[XSnch?= NYfBfmlncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MVKyOVEzOzB6Mh?=
Eca109 M{\lVWZ2dmO2aX;uJGF{e2G7 M4L4TVAvPcLizszN M2D6S|YwOTJxMkSgbC=> NVXEfpZsf2G2ZYK= NVfrVW93cW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> M2LHSVI2OTJ|MEiy
Eca109 MkPpSpVv[3Srb36gRZN{[Xl? MYewMlXDqM7:TR?= NX7QZ21vOjRiaB?= MYj3ZZRmeg>? MYTpcohq[mm2czDj[YxtKGmwdnHzbY9v MnT1NlUyOjNyOEK=
Eca109 M3;kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmwS3RnOC53wrFOwG0> MnPhNlQhcA>? NGPqN5h4[XSnch?= NULBTm42cW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? MkjpNlUyOjNyOEK=
Eca109 NECwT3RHfW6ldHnvckBCe3OjeR?= MVSwMlUwOSEQvF2= NV3zU3VNOjRiaB?= NFzZfWR4[XSnch?= NYn6OVZK\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= NE\odHQzPTF{M{C4Ni=>
SW1116  NFnyd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMlUwOS9{L{Wg{txO NHHSXWk1QCCq M13kVmROW09? MnGy[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MVqyOFg4PDJ6Nh?=
LOVO NGf0SYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XTZlAvPS9zL{KvOUDPxE1? NGThUoo1QCCq NXXtcnR[TE2VTx?= NXPpZ4RY\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M2OyelI1QDd2Mki2
SW1116  Mn\LSpVv[3Srb36gRZN{[Xl? NXzWWWJEOTBizszN NH\UdJU1QCCq MX\EUXNQ NGDH[5NqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M{LqdVI1QDd2Mki2
LOVO NXniXHpvTnWwY4Tpc44hSXO|YYm= MVixNEDPxE1? MYm0PEBp MmPxSG1UVw>? MnHEbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj M4PBe|I1QDd2Mki2
SW1116  NXLkSmVGSXCxcITvd4l{KEG|c3H5 M3XXOVExKM7:TR?= MXi0PEBp NUfLVFhbTE2VTx?= M2jK[YVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnzMNlQ5PzR{OE[=
LOVO MYrBdI9xfG:|aYOgRZN{[Xl? NFrMXlkyOCEQvF2= M4X0e|Q5KGh? M2D1emROW09? NHT1XXhmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> M1z1dFI1QDd2Mki2
RPMI-8226 M{fVRWFxd3C2b4Ppd{BCe3OjeR?= NVTkNllkOS9{IN88US=> M{HiUlQ5Nzd{L{m2JIg> Mki5SG1UVw>? M2nYfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3TWUVI1QDN|MUC4
OPM-2  NHLycYtCeG:ydH;zbZMhSXO|YYm= NFzPclUyNzJizszN MY[3Nk86Pi9zMkCgbC=> NHjWOI9FVVOR NFvHfmZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MV:yOFg{OzFyOB?=
JJN3  MnWwRZBweHSxc3nzJGF{e2G7 NGXMU|QxNjVxMTFOwG0> NYL4eo5{OjRxNEigbC=> MYXEUXNQ M2PyN4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXLObo9oOjR6M{OxNFg>
NCI-H929  MWXBdI9xfG:|aYOgRZN{[Xl? M{H3OVEwOiEQvF2= MWS3Nk86Pi9zMkCgbC=> M4LoUGROW09? MljubY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4XjNFI1QDN|MUC4
RPMI-8226 M2PFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXBXodCOS9{IN88US=> NXfiR4FWOjRxNEivO|IhcA>? M3rZ[WROW09? MkHZZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NVvBdYhOOjR6M{OxNFg>
OPM-2  M1i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5NU8zKM7:TR?= MWGyOE81QC95MjDo NXP4T3JFTE2VTx?= MX3h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NYjDeZh5OjR6M{OxNFg>
JJN3  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlUwOSEQvF2= NWLCcYh3OjRxNEivO|IhcA>? MlH5SG1UVw>? M2LLWYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NEPTOFUzPDh|M{GwPC=>
NCI-H929  NITq[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3wN3hzOS9{IN88US=> MVGyOE81QC95MjDo NIXONnlFVVOR NV3H[FVJ[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NGDN[GMzPDh|M{GwPC=>
HeLa NIjGbI1McW6jc3WgRZN{[Xl? Mk[0T4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> NVTibG5HOjR5OECwPVg>
HeLa NFTxeJZMcW6jc3WgRZN{[Xl? NWK5TXhYU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MlXzNlQ4QDByOUi=
HeLa NHXFOlRMcW6jc3WgRZN{[Xl? MVfLbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx NFXqd4ozPDd6MEC5PC=>
HeLa M360SmtqdmG|ZTDBd5NigQ>? NG[zTpBMcT1zND60JOKyKDRwNjFOwG0h\m:{IHjDUnQ{ MlHyNlQ4QDByOUi=
NB4 NWXHU4xUTnWwY4Tpc44hSXO|YYm= NWLnVXJ3Oi53L{WvO{42NzFyIN88US=> NFnDeZczPCCq MWXEUXNQ Mmn5bY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MXqyOFQ5PDh5MB?=
CD4+ CD25− T  MX;GeY5kfGmxbjDBd5NigQ>? MmfKNU82KM7:TR?= MXfy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> NE\NTFQzPDR5NkO2NC=>
BV-173 M2XMc2Fxd3C2b4Ppd{BCe3OjeR?= Mn7WNE4zPS9yLkWvNE44PS9zIN88US=> NWXmdo97PDhxN{KvPVYhcA>? M1y4UuKhWEKV MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M2rMO|I1PDJ|NkGz
ML-1 NXHsVGNuSXCxcITvd4l{KEG|c3H5 MXWwMlI2NzBwNT:wMlc2NzFizszN M4njbVQ5Nzd{L{m2JIg> NVS5W5EyyqCSQmO= NGX2bphqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NInJ[3IzPDR{M{[xNy=>
HL-60 Mo\VRZBweHSxc3nzJGF{e2G7 NFXoco4xNjJ3L{CuOU8xNjd3L{Gg{txO MXK0PE84Oi97NjDo M4HkeuKhWEKV MUHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MWSyOFQzOzZzMx?=
KG-1a MojkRZBweHSxc3nzJGF{e2G7 MXOwMlI2NzBwNT:wMlc2NzFizszN NXWzfnVGPDhxN{KvPVYhcA>? MVRCpHBDWw>? MWPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MnfsNlQ1OjN4MUO=
BV-173 NHPXellHfW6ldHnvckBCe3OjeR?= M3XlVVI2OC93MEDuUS=> NYHzZ25XPDhiaB?= NXezeox1yqCSQmO= MkDXbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M3iwcFI1PDJ|NkGz
CEM NInaVmZHfW6ldHnvckBCe3OjeR?= MojhNlUxNzVyMH7N MYC0PEBp NX73eHo1yqCSQmO= M{LySIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MY[yOFQzOzZzMx?=
HL-60 NUGyUIpbTnWwY4Tpc44hSXO|YYm= M2DlblI2OC93MEDuUS=> NWXhPY1iPDhiaB?= Mlm4xsBRSlN? Mn[1bY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NXPyPIlLOjR2MkO2NVM>
ML-1 NFP1TWxHfW6ldHnvckBCe3OjeR?= MYSyOVAwPTBybl2= NVj4NYtwPDhiaB?= MWdCpHBDWw>? M1;hZYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MlLWNlQ1OjN4MUO=
DLD-1 M{DsTGZ2dmO2aX;uJGF{e2G7 NFrlUo8zPTBxNUCwcm0> MUm0PEBp M3nxZuKhWEKV NX;VNVVT\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NVfuN3NMOjR2MkO2NVM>
HCT-116 NXrVbYtXTnWwY4Tpc44hSXO|YYm= MlixNlUxNzVyMH7N MoLqOFghcA>? NUHvW|BDyqCSQmO= NUPEVnJK\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NVPVUXMyOjR2MkO2NVM>
U937-A/E-9/14/18  MXfBdI9xfG:|aYOgRZN{[Xl? NX3WRY1yOC5yMT:wMlEwOS9zMDFOwG0> NUXu[YJ4PDhiaB?= MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MknoNlQ{ODB2NU[=
HT29 NEW1TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp NXLLXZBxUUN3ME2xOFAxyrFzN{mg{txO NHfWTHQzPDF5MkC2NS=>
SW48 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjBO|M4OiCq NInBcpNKSzVyPUG1MlLDuTZwMjFOwG0> MoXFNlQyPzJyNkG=
HCT116 M4DRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH1VotpPzJiaB?= NIfNdHRKSzVyPUGuO:KyOC52IN88US=> MW[yOFE4OjB4MR?=
HepG2 Ml;wSpVv[3Srb36gRZN{[Xl? M3rrclAvPS9zIN88US=> MlHRNlQhcA>? MoPKSG1UVw>? MWX1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? M1izdVI1OTR4OEe0
LS174T MmTsSpVv[3Srb36gRZN{[Xl? MmjwNE42NzFizszN NISxN4EzPCCq NIfobZNFVVOR MX3s[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= MX:yOFE1Pjh5NB?=
HepG2 NETFZm1CeG:ydH;zbZMhSXO|YYm= M4DhRVEwOTBxMUCwJO69VQ>? M{XaeFch\A>? NXTkUpd7TE2VTx?= NWDENIhHcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoT3NlQyPDZ6N{S=
LS174T M1Lh[WFxd3C2b4Ppd{BCe3OjeR?= MnrNNU8yOC9zMECg{txO NF24WW44KGR? NYDkO|ZkTE2VTx?= NHvaeVZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{\rS|I1OTR4OEe0
QBC-939 MoKwRZBweHSxc3nzJGF{e2G7 NHPFNWkyNzFyL{GwNEDPxE1? M3PvNlch\A>? NEHvfnRFVVOR M1HNfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX3zXmpYOjRzNE[4O|Q>
U251 MXXBdI9xfG:|aYOgRZN{[Xl? MkjwNU8yOC9zMECg{txO NHHiPHU4KGR? Mly5SG1UVw>? M{G0dolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml3pNlQyPDZ6N{S=
HL-60 NI[x[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\G[4ZsOSEQvF2= MkS2OFghcA>? NFj0bHpqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MYeyOFAxODN{NB?=
MDA‑MB‑453 Ml\nSpVv[3Srb36gRZN{[Xl? MonYNE4zNzFizszN MYC3NkBp M1j1ZYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MnzqNlM5PDR{Mki=
HCC1569 M4XscGZ2dmO2aX;uJGF{e2G7 Mk\wNE4zNzFizszN MVm3NkBp NW\X[YZn[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MUSyN|g1PDJ{OB?=
BT‑474 MoewSpVv[3Srb36gRZN{[Xl? M4fT[VAvOi9zIN88US=> MXe3NkBp M4j1eYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NGjzR|IzOzh2NEKyPC=>
AGS NILaW5pCeG:ydH;zbZMhSXO|YYm= M1PUdFUwOTBxMkCvOVAh|ryP NVzFU402PDkEoHlCpC=> M{jrcGROW09? M3rXe4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh Ml3ENlM2QDJ5OES=
A549 M1TqTWFxd3C2b4Ppd{BCe3OjeR?= MVO1M|ExNzJyL{WwJO69VQ>? MmjUOFjDqGkEoB?= MojOSG1UVw>? M{fXNYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NWP0RYF5OjN3OEK3PFQ>
AGS  NGLOW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK1M|ExNzJyL{WwJO69VQ>? MnTCOFjDqGkEoB?= MW\EUXNQ NUDMTYNRcW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh M1OyeVI{PTh{N{i0
Kasumi-1 M3LVT2Fxd3C2b4Ppd{BCe3OjeR?= MVywMlUh|ryP MXy0POKhcMLi M3TDPIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NH;OU28zOzR7M{O0PC=>
OCI-AML3 MoLTRZBweHSxc3nzJGF{e2G7 MnThNk42KM7:TR?= NFzjR3c1QMLiaNMg NGLNUohl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NGrU[o0zOzR7M{O0PC=>
MV4-11 NHnidnJCeG:ydH;zbZMhSXO|YYm= NH7FdYczNjVizszN NYLwS2pyPDkEoHlCpC=> M{jUWYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MW[yN|Q6OzN2OB?=
NK  M{DocWN6fG:2b4jpeJkhSXO|YYm= MoTiNE4xOi1{MDFOwG0> NGrWV3o2KGR? NFXZNnBl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n MkjBNlM{OjhyOEi=
NK  MljDRZBweHSxc3nzJGF{e2G7 NXzn[YFqOC5yMj2yNEDPxE1? MVO1JIQ> MlLB[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MVKyN|MzQDB6OB?=
NK  M2XmPGZ2dmO2aX;uJGF{e2G7 MYqwMlAyNTJyIN88US=> Mo\uOUBl M1XVZ4NifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> NFq4ZnYzOzN{OEC4PC=>
MOLT4/DNR NVu5WXFkTnWwY4Tpc44hSXO|YYm= NGWxd2o2KM7:TR?= MV:0JIQ> M4LBcZJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v MX6yN|A3ODV5MB?=
Jurkat/DOX NUjzc41zTnWwY4Tpc44hSXO|YYm= MYW1JO69VQ>? MWC0JIQ> NYfGXpQ4emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? NYO3[W5kOjNyNkC1O|A>
MOLT4/DNR M4LPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TnW|Uh|ryP MV20JIQ> NUPQSoU{emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M{fadFI{ODZyNUew
Jurkat/DOX NH;UVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK1JO69VQ>? NFSyTZQ1KGR? NUDNd3VMemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MWOyN|A3ODV5MB?=
ccRCC  NUjFS4o2SXCxcITvd4l{KEG|c3H5 Mkj6NE4xOS1zMN88US=> MmTNO|IhcA>? MnW4SG1UVw>? MUToZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NH\TdXMzOjh{NkS2Oy=>
TNBC  MYnBdI9xfG:|aYOgRZN{[Xl? MXiwMlAyNTFyzszN NWnIWZdFPzJiaB?= Mm\4SG1UVw>? NIO2UJBp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NUf3[GZLOjJ6Mk[0Olc>
A498 NHyxcplCeG:ydH;zbZMhSXO|YYm= MYmwMlAyNTFyzszN M{HzZVczKGh? MnK4SG1UVw>? NXr0fVZ3cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MU[yNlgzPjR4Nx?=
KIJ265T M332dGFxd3C2b4Ppd{BCe3OjeR?= MlP3NE4xOS1zMN88US=> NFX1e3E4OiCq Mnz4SG1UVw>? NYPrPYc5cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MVeyNlgzPjR4Nx?=
MDA-231 NGrxWVBCeG:ydH;zbZMhSXO|YYm= NY\2[Iw4OC5yMT2xNO69VQ>? M17HXFczKGh? MVHEUXNQ MYDpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NXHDWnZ7OjJ6Mk[0Olc>
BT-20 NHWxdGFCeG:ydH;zbZMhSXO|YYm= M{DjeVAvODFvMUFOwG0> MUC3NkBp NXH3cHhNTE2VTx?= MnOybY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NUPFdZJ4OjJ6Mk[0Olc>
U937 M1zxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES3TlI2NTJyIN88US=> NYPDWWRtOjRxNEivO|IhcA>? MmfXbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MmLINlI4PjdyMkG=
HL60 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH2Rm1pPS1{MDFOwG0> M2O3TVI1NzR6L{eyJIg> NH\IRXhqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NEezWnczOjd4N{CyNS=>
U937 NHn1fHhCeG:ydH;zbZMhSXO|YYm= NUPMUlNjOTVizszN MUKyOE81QC95MjDo MnH0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mn7ONlI4PjdyMkG=
HL60 MYHBdI9xfG:|aYOgRZN{[Xl? MVWxOUDPxE1? NWG4PVZiOjRxNEivO|IhcA>? M320Solv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIG0R3YzOjd4N{CyNS=>
LS411N  NVPq[WVSSXCxcITvd4l{KEG|c3H5 MlfhNE42KM7:TR?= MmDHO|IhcA>? NX:1R3JtcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs M1P3blIzPDZzNkm1
MDA-MB-231 NX;HdFFZSXCxcITvd4l{KEG|c3H5 M3:wblExKM7:TR?= NVmwOHh6PDhiaB?= MljIdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkDDNlE5QDd4OUe=
MCF-7  NHvUWHZCeG:ydH;zbZMhSXO|YYm= MWSxNEDPxE1? MV[0PEBp MkjudoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXzOfJNLOjF6OEe2PVc>
A375 NGWyVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmwMlUh|ryP NXvjR4R1OS93L{ig[C=> MkjzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MlTyNlE4QTZ4MkK=
SKMEL1 NUjKS|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:5WG4xNjVizszN MoW0NU82NzhiZB?= NWjIdoxncW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NGHHdmYzOTd7Nk[yNi=>
SKMEL3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO0cXlYOC53IN88US=> Mmn6NU82NzhiZB?= M4\MZ4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MmHSNlE4QTZ4MkK=
SKMEL28 NH;qboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn1T|cxNjVizszN M4HGc|EwPS96IHS= MlLobY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MWqyNVc6PjZ{Mh?=
MeWo NWrRTpE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfBd2pvOC53IN88US=> NH7lVpAyNzVxODDk MW\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MXKyNVc6PjZ{Mh?=
B16 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLONE42KM7:TR?= M{DhcVEwPS96IHS= MY\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NXf3enRGOjF5OU[2NlI>
Ly 1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HkeVI1KGh? NWTiO2MzUUN3ME23MlMh|ryP NGO0eo8zOTd5MkC0PS=>
Ly 7 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fWTlI1KGh? M3y0fGlEPTB;MUCuO{DPxE1? NFrJe3MzOTd5MkC0PS=>
Su-DHL6 M{nifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSyOEBp NHPVVnlKSzVy78{eNlAh|ryP M2SweVIyPzd{MES5
Ly 10 NUDsfWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2yOEBp NHnqTXVKSzVy78{eNlAh|ryP MWiyNVc4OjB2OR?=
RIVA NFvlVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HycVI1KGh? M2DNNmlEPTExvK6yNEDPxE1? NUL2V2RNOjF5N{KwOFk>
Su-DHL2 NUTBeoo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HSSFI1KGh? MmnzTWM2OO,:nkKwJO69VQ>? M{Ppd|IyPzd{MES5
Ly 1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPzS|g5PDhiaB?= MYDJR|UxRTBwM{Sg{txO NGjHV4UzOTd5MkC0PS=>
Ly 7 NIH0WHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm0PEBp M4S5R2lEPTB;MD6wNlUh|ryP MXGyNVc4OjB2OR?=
Su-DHL6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O1WFQ5KGh? MX3JR|Ux97zgMkCg{txO MWWyNVc4OjB2OR?=
Ly 10 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\pN|Q5KGh? NXjqVZROUUN3ME2xMlgh|ryP MoL6NlE4PzJyNEm=
RIVA M2fUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PjWFQ5KGh? NWi2cnRYUUN3MP-8olIxKM7:TR?= MWiyNVc4OjB2OR?=
Su-DHL2 NU\rUYVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG0PEBp NEj1NlFKSzVyPUG3MlQh|ryP MoLmNlE4PzJyNEm=
Ly 1 NFPSZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfwOZlIPzJiaB?= Ml\XTWM2OD1yLkCxJO69VQ>? NYroe4pXOjF5N{KwOFk>
Ly 7 NWfOeYsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfpO|IhcA>? MX7JR|UxRTBwMEG4JO69VQ>? NVPJNYF6OjF5N{KwOFk>
Su-DHL6 M33G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mxVVczKGh? NVnVd|JzUUN3ME2xMlYh|ryP NW\5eWxzOjF5N{KwOFk>
Ly 10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjGXos4OiCq M2HVfGlEPTB;MT6yJO69VQ>? M13CcVIyPzd{MES5
RIVA MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnR[3JsPzJiaB?= NETzeY9KSzVy78{eNlAh|ryP MYSyNVc4OjB2OR?=
Su-DHL2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT2VnE4OiCq NYnH[nM3UUN3ME2xNU4zKM7:TR?= MoDCNlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID